Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 5, 2018 in Prostate cancer | 0 comments

In a nutshell

This study examined rates of biochemical relapse after using intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB) in men with low and intermediate stage prostate cancer. This study found that rates of biochemical relapse were low after treatment. 

Some background

Prostate cancer can be treated during surgery using a low-dose prostate radiation delivered with an automated delivery system. This is called intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB). This treatment can be used for low and intermediate risk prostate cancer patients. The long-term effectiveness of this treatment is still under investigation. 

Methods & findings

Between 2003 and 2013, 2608 patients from 3 centers were treated with IO-LDRB and were followed up for more than 5 years. These patients were monitored using their PSA levels (a protein present in prostate cancer). When PSA levels rose, it was defined as a biochemical relapse of the original prostate cancer. 

Biochemical relapse was seen in 124 patients (4.8%). Biochemical relapse occurred at an average of 4 years after treatment. It was predicted that biochemical relapse free survival was 93% at 7 years. 

The bottom line

This study found that rates of biochemical relapse remain low at 4.8% several years after treatment. 

The fine print

This was a prospective study, and so has a good level of evidence. 

Published By :

International journal of radiation oncology, biology, physics

Date :

Nov 15, 2017

Original Title :

Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.

click here to get personalized updates